Spectrum Pharmaceutecals Inc (SPPI)

[antihama]

Here's another Evomela P2 study (NCT01969435) sponserd by the Washington School of Medicine. This one is interesting in that it combines BEAM (Carmustine, Etoposide, and Cytarabine ) treatment prior to high dose peg-free melphalan (Evomela). Essentially the patient is getting 2 myleeoablative treatments instead of just Evomela that was used for approval. They are looking at 2 yr response and the study stopped recruiting a year ago (Nov 3, 2015) so results top line results should be available by end of next year.